Ersofermin

Ersofermin
[[File:|frameless|220px|alt=|]]
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Ersofermin is a recombinant human fibroblast growth factor 19 (rhFGF19) analog that is being investigated for its potential therapeutic effects in treating metabolic disorders, particularly non-alcoholic steatohepatitis (NASH). It is designed to mimic the activity of the naturally occurring FGF19, a hormone involved in regulating bile acid synthesis, glucose metabolism, and lipid metabolism.

Mechanism of Action

Ersofermin functions by activating the FGF receptor 4 (FGFR4) and its co-receptor β-Klotho, which are primarily expressed in the liver. Upon activation, these receptors initiate a signaling cascade that results in the suppression of bile acid synthesis, improvement in insulin sensitivity, and reduction of liver fat accumulation. This makes Ersofermin a promising candidate for addressing the underlying pathophysiology of NASH, which is characterized by liver inflammation, fat accumulation, and fibrosis.

Clinical Development

Ersofermin is currently undergoing clinical trials to evaluate its safety and efficacy in patients with NASH. Early-phase studies have shown that Ersofermin can significantly reduce liver fat content and improve liver function markers. Ongoing trials aim to further assess its impact on liver histology and long-term outcomes in NASH patients.

Potential Benefits

The potential benefits of Ersofermin in treating NASH include:

• Reduction in liver fat content
• Improvement in liver enzyme levels
• Decrease in liver inflammation and fibrosis
• Enhancement of insulin sensitivity

Side Effects and Safety

As with any investigational drug, the safety profile of Ersofermin is being closely monitored in clinical trials. Commonly reported side effects include gastrointestinal disturbances, such as nausea and diarrhea, as well as potential alterations in lipid profiles. Long-term safety data are still being collected.

Regulatory Status

Ersofermin is not yet approved for clinical use and is available only through participation in clinical trials. The results of ongoing studies will determine its future regulatory approval and availability.

Also see

• Non-alcoholic steatohepatitis
• Fibroblast growth factor 19
• Liver disease
• Metabolic syndrome